Protein Domain Linked To Tumor Progression Isolated
Thursday, February 19, 2009 - 21:35
in Health & Medicine
When a promising cancer drug reached clinical trials in the 1990s, researchers were disappointed by the debilitating side effects that limited the trials. The drug inhibited a family of enzymes known as matrix metalloproteinases. Now, researchers have shown that creating drugs that inactivate a different part of the MMP enzyme could have the capacity to target the tumor without the damaging side effects. Their findings hold promise for improved cancer therapies.
Read the whole article on Science Daily
More from Science Daily
Related
- Researchers isolate protein domain linked to tumor progressionTue, 17 Feb 2009, 18:57:15 EST
- Revolutionary drug could be new hope for adrenal cancer patientsTue, 22 Sep 2009, 12:50:19 EDT
- Enzyme may hold key to improved targeting of cancer-fighting drugsThu, 29 May 2008, 17:07:50 EDT
- New cancer drug test promises safer and more effective clinical trialsWed, 23 Sep 2009, 7:37:16 EDT
- CSHL scientists identify new drug target against virulent type of breast cancerMon, 25 Aug 2008, 11:16:05 EDT